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Chronic diarrhoea is a common condition, resulting from a number of different disorders.  Bile acid 
diarrhoea, occurring in about a third of these patients, is often undiagnosed.  We hypothesised that 
a positive diagnosis of BAD would reduce the need for subsequent investigations for alternative 
diagnoses. 
Methods:  Patients previously recruited to a study of chronic diarrhoea who had SeHCAT testing and 
subsequent follow-up at our institution were identified.  In a retrospective analysis, the numbers of 
defined investigations undertaken from the first three months after SeHCAT in the following 5 years 
were compared. 
Results:  90 patients were identified with primary bile acid diarrhoea (SeHCAT retention <15%, n=36) 
or idiopathic diarrhoea (SeHCAT retention >15%, n=54).  Follow-up had been performed on 29 and 
39 subjects respectively, with no differences in previous investigations or the last contact date.   In 
the follow-up period, the proportions of these patients who had undergone endoscopic procedures 
(gastroscopy, colonoscopy, sigmoidoscopy) were the same.  However, there was a higher proportion 
of patients in the SeHCAT-negative group who had undergone other investigations, including 
imaging, physiological tests and blood tests (p=0.037).  Use of cross-sectional imaging was 
significantly higher in this group (p=0.015) with greater proportions of subjects having CT (0.44 vs. 
0.10) and MRI (0.26 vs. 0.07).  Ultrasound use and the number of blood tests were also higher in the 
SeHCAT-negative group whereas the SeHCAT-positive group attended more clinic appointments 
(p=0.013).   
Conclusion:  A positive diagnosis of bile acid diarrhoea, made by a SeHCAT test, resulted in reduced 
use of diagnostic investigations over the subsequent five years.  
 
  




































































Chronic diarrhoea is a common presenting problem in primary and secondary care in the UK and 
elsewhere.  After conditions including inflammatory bowel disease (ulcerative colitis and Crohn’s), 
microscopic colitis, coeliac disease and colonic neoplasia have been excluded, many patients are told 
they have functional causes for the diarrhoea.
1
  Functional chronic diarrhoea and irritable bowel 
syndrome (IBS) with diarrhoea are overlapping condition and estimates suggest 3% of the population 
may suffer from these. 
 
It has been shown in multiple studies that around 25-33% of these people with functional chronic 
diarrhoea have primary bile acid diarrhoea (PBAD), also known as idiopathic bile acid malabsorption 
(BAM).
2,3
  Diagnostic methods have been reviewed recently.
4
  The SeHCAT test uses tauroselcholic  
5
 
acid (SeHCAT) to identify excessive faecal bile acid loss by measuring whole body retention of radio-
labelled 
75 
Se by gamma camera at 7 days.  Retention values between 10 and 15% indicate mild bile 
acid loss, those between 5 and 10% moderate, and less than 5% indicating severe loss.  Patients with 
PBAD will usually show a response to bile acid sequestrants such as colestyramine or colesevelam.
6
  
Alternative diagnostic methods include measurement in blood of a bile acid precursor, 7α-OH-4-
cholestenone (C4), faecal bile acid quantification or a therapeutic trial of treatment. 
 
Clear recognition and quantification of the excessive bile acid loss in PBAD enables the therapeutic 
options to be refined and modified so that optimal individualised patient responses can be 
obtained.
7,8
  Although such expert opinion recognises the value of SeHCAT testing in clinical practice, 
an economic review for NICE in 2012 found there was insufficient data for clear conclusions to be 
drawn.
9
  Guidelines for the investigation of chronic diarrhoea are in need of updating 
10
 and recent 
patient-reported symptoms and outcomes suggests many patients suffer for over 5 years as clinician 




A potential benefit of a timely diagnosis of PBAD is that this could result in fewer investigations 
being performed to look for possible alternative diagnoses.  This has not been assessed previously. 
We hypothesised there would be a lower subsequent use of investigations in patients who had a 
positive SeHCAT result.  The aim of this study was to provide initial data on the use of investigations 
following a SeHCAT test to help in the evaluation of any economic benefit of an abnormal SeHCAT 
test. 
  





































































We previously recruited patients with chronic diarrhoea to a prospective study of chronic diarrhoea 
between January 2009 and July 2010.
12
  They had all had SeHCAT testing and subsequent follow-up 
at our institution as part of a study approved by the Research Ethics Committee of Hammersmith 
and Queen Charlottes & Chelsea hospitals.  Their clinical features have been described before.
12
  We 
have now retrospectively analysed the investigations they had at the time of diagnosis and 
subsequently. 
 
Two cohorts of patients were studied.  The group with bile acid diarrhoea had a SeHCAT 7-day 
retention value of <15% (“SeHCAT positive”).  Only those with PBAD were included; patients with 
secondary causes including Crohn’s disease, ileal resection or post-cholecystectomy diarrhoea were 
excluded.  The second group of idiopathic chronic diarrhoea (“SeHCAT negative”) had a SeHCAT 7-
day retention >15%.  The cohorts were then restricted to those who had continued to be seen in any 
department of our healthcare trust for 5 years from the date of their SeHCAT investigation. 
 
Investigations 
Electronic medical records were searched systematically to identify the number, type and indication 
for defined pertinent investigations in all patients in the cohort.  This included clinical 
correspondence, outpatient appointment, endoscopy, radiology, physiology and pathology report 
databases.  Any overlap was accounted for. 
 
Investigations undertaken for 5 years from the date of the SeHCAT scan in all patients were 
identified.  Tests carried out within 3 months of the SeHCAT test date were analysed separately, as 
they were likely to have been ordered before the SeHCAT result was known.  Any investigations 
undertaken after the 5-year follow-up period were not included.  
 
All investigations performed for a gastro-intestinal condition, or relevant symptoms, were counted.  
These included: gastroscopy, colonoscopy, flexible sigmoidoscopy, ERCP, capsule endoscopy, CT, 
MRI, PET, US, abdominal X-ray, glucose- and lactose-hydrogen breath testing.  All blood tests were 
recorded.  Out-patient visits were identified, but only gastroenterology appointments following the 
SeHCAT result appointment were counted in order to assess the impact on subsequent follow-up.  
 



































































The number of specific and pooled investigations per patient and per group was compared between 
the two groups.  Median numbers of investigations were compared by non-parametric Mann-





A total of 114 patients from the previous study were seen at our institution and of these, 90 patients 
were identified with possible primary bile acid diarrhoea (SeHCAT <15%, n=36) or idiopathic 
diarrhoea (SeHCAT >15%, n=54).  Follow-up date was available on 29 “SeHCAT-positive” and 39 
“SeHCAT-negative” patients respectively (Table 1).  There was no difference between these groups 
in the date of the last contact in our institution or the length of follow-up.  Two patient included in 
the SeHCAT-negative group had died from unrelated conditions.  The clinical features of the two 
groups did not differ from those we described before.
12
  Endoscopic and other investigations were 
performed in similar proportions before the SeHCAT test (Table 1).  There was also no difference in 
the number of these investigations performed in the 3 months immediately following the SeHCAT 
test (Table 2), which could have been ordered as part of the initial evaluation of diarrhoea. 
 
Investigations 
In the 5-year follow-up period, there was no significant difference in the proportion of patients who 
had undergone endoscopic procedures including gastroscopy, colonoscopy, flexible sigmoidoscopy, 
capsule enteroscopy and ERCP (Table 3).  However, there were statistically significant greater 
proportions of the SeHCAT-negative group who underwent investigat ons when all imaging (CT, MRI, 
US), physiological tests and blood tests were analysed (p=0.037).  Use of cross-sectional imaging 
(abdominal CT and MRI) was particularly higher in the SeHCAT-negative group (p=0.018).  US use did 
not differ significantly.  Six patients (five SeHCAT-negative, one SeHCAT-positive) had both CT and 
MRI. 
 
More blood tests had been undertaken in the SeHCAT-negative group compared to the SeHCAT-
positive group.  This did not reach significance (p=0.085).  However, the SeHCAT-negative patients 
had fewer gastroenterology out-patient clinic appointments than the SeHCAT-positive patients 
during the 5 year period of follow-up (p=0.013).  As expected, the SeHCAT-negative patients had 
greater variability in both number of blood tests and in follow-up appointments. 





































































This study has been performed to give initial data regarding how a positive diagnosis of primary BAD, 
made by SeHCAT testing, influences subsequent use of investigations over a 5-year period in a 
cohort of patients presenting with chronic diarrhoea.  The greatest difference found was in the use 
of cross-sectional abdominal imaging by CT and MRI.   
 
There are many causes of chronic diarrhoea, with primary BAD being found in a large proportion –
36% in the prospective series which included the patients studied here.
12
  The diagnosis can be made 
by SeHCAT scanning in a relatively simple, non-invasive procedure, which gives a greater proportion 
of positive results than other, less proven tests.
4
  Patients value having the correct diagnosis made in 
a timely fashion; almost half of those in a recent survey had waited for more than 5 years and felt 
that their symptoms had been dismissed before they were diagnosed with PBAD.
11
  Treatment with 
bile acid sequestrants is effective in a majority, as demonstrated in 75% of these patients in our 
previous publication.
12
  There are clearly patient benefits in being diagnosed in a timely manner.  We 
have shown that there are also likely to be economic and organisational benefits in the usage of 
other diagnostic resources. 
 
The use of endoscopic procedures to rule out important causes of chronic diarrhoea such as 
colorectal cancer and inflammatory bowel disease was similar in both groups.  The BSG guidelines 
from 2003 
10
 are currently undergoing revision and are expected to place the exclusion of these 
diseases as a high priority.  Our data indicates that exclusion of BAD by SeHCAT will result in less use 
of cross-sectional imaging by CT and/or MRI.  These are usually performed to exclude possible 
chronic pancreatic disease or small bowel pathology, not found on endoscopy or ruled out by other 
tests.  The yield of these tests in our series of patients was very low but they are still likely to be 
performed if no definite diagnosis has been made in a symptomatic patient.  Further tests will also 
be performed in the minority (25%) of SeHCAT patients who do not experience a satisfactory, full 
response to bile acid sequestrants.
12 
 
These results provide some data to help in the assessment of the economic benefits of diagnosing 
PBAD.  We can assume that the SeHCAT-positive patients, had they not been diagnosed, would have 
had the same utilisation of other tests as the SeHCAT-negative patients.  Using the difference in 
proportions undergoing these tests and their NHS unbundled tariffs,
13
 net savings per patient would 
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7 
 
be: from CT (0.34x£135=£46), MRI (0.19x£240=£46) and US (0.17x£56=£10) = £102.  There would be 
further saving from the costs of blood tests.  A more detailed study is needed to assess fully the 
economic benefits of potential improvements in the quality of life, including any reduction in 
primary care visits, as opposed to treatment and follow-up costs, and the cost of SeHCAT, in making 
the diagnosis of PBAD. 
 
There are several limitations to our study.   The size of the cohorts is not large, which has limited the 
power to detect significant differences.  The analysis of these investigations has been performed 
retrospectively and we did not follow any specific defined protocols for further investigation or 
treatment but left these to the clinical judgment of the referring clinician.  Although we have 5-year 
follow-up data on subsequent investigations, we cannot be certain that the patients have not 
attended other hospitals for investigations.  However, as there were more out-patient attendances 
in the SeHCAT-positive group, but more investigations in the SeHCAT-negative group, this difference 
is likely to be greater if further investigations had been performed elsewhere.  Furthermore, the 
greater number of out-patient attendances in the SeHCAT-positive group likely results from 
continued follow-up of these patients for potential therapeutic research and so may not be 
generalizable. 
 
In conclusion, this study has shown that in a cohort of patients with chronic diarrhoea, there is a 
lower usage of other investigations in those with a diagnosis of PBAD in the five years after a SeHCAT 
test.  This provides additional data to support measures to increase the awareness of bile acid 
diarrhoea and the benefits of making a positive diagnosis. 
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Table 1: Patient details and investigations performed before SeHCAT testing 
 SeHCAT positive  SeHCAT-negative  
 (<15%)  (>15%)  
 Number Tests/patient  Number Tests/patient  
No. of patients       
Diagnosed 36   54   
With 5 year follow up 29   39   
SeHCAT (7-day % retention)       
Mean 9.0   33.9   
Minimum 3.0   15.6   
Maximum 14.4   90.0   
Investigations before SeHCAT       
Endoscopy       
Colonoscopy 16 0.55  20 0.51  
Flexible sigmoidoscopy 6 0.21  7 0.18  
Gastroscopy 8 0.28  12 0.31  
Physiology       
 Glucose hydrogen-breath test 2 0.07  4 0.10  
Lactose hydrogen-breath test 7 0.24  3 0.08  
       
Data are shown as proportions of the patients in each group with 5-year follow up. 
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Table 2: Investigations performed in the 3 months after SeHCAT testing 
 
 SeHCAT positive  SeHCAT-negative  
 (<15%)  (>15%)  
 Number Tests/patient  Number Tests/patient  
No. of patients 29   39   
Endoscopy       
Colonoscopy 5 0.17  8 0.21  
Flexible sigmoidoscopy 0 0.00  0 0.00  
Gastroscopy 4 0.14  2 0.05  
Physiology       
 Glucose hydrogen-breath test 0 0.00  3 0.08  
Lactose hydrogen-breath test 8 0.28  8 0.21  
       
  



































































Table 3:  Investigations performed between 3 months and 5 years after SeHCAT testing 
 SeHCAT positive  SeHCAT-negative  
 (<15%)  (>15%)  
 Number Tests/patient  Number Tests/patient  
No. of patients 29   39   
Endoscopy       
Colonoscopy 6 0.21  7 0.18  
Flexible sigmoidoscopy 0 0.00  4 0.10  
Gastroscopy 6 0.21  4 0.10  
       
Imaging       
CT  3 0.10  17 0.44 
a 
MRI  2 0.07  10 0.26  
CT or MRI 5 0.17  27 0.70 
b 
US  16 0.55  28 0.72  
Abdo X-ray  9 0.31  15 0.38  
       
Physiology       
 Glucose hydrogen-breath test 1 0.03  2 0.05  
Lactose hydrogen-breath test 0 0.00  3 0.08  
Other investigations  3 0.10  5 0.13  
       



























 p=0.015 two tailed Fisher’s exact test. 
c
  p=0.086; 
d
 p=0.013; Mann-Whitney U-test. 
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